HAEMONETICS CORP/MASS (HAE) Stock Analyst Ratings
USA - New York Stock Exchange - NYSE:HAE - US4050241003 - Common Stock
81.35 USD
+0.6 (+0.74%)
81.35 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 81% to HAE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 88.03. This target is 8.21% above the current price.
HAE was analyzed by 15 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about HAE.
In the previous month the buy percentage consensus was at a similar level.
HAE was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-21 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-07 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-11-07 | Needham | Maintains | Buy -> Buy |
| 2025-11-06 | BTIG | Maintains | Buy -> Buy |
| 2025-10-21 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-10-07 | Citigroup | Maintains | Buy -> Buy |
| 2025-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2025-08-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-08-08 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-08-08 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-08-07 | Needham | Maintains | Buy -> Buy |
| 2025-07-11 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-07-09 | Citigroup | Upgrade | Neutral -> Buy |
| 2025-06-26 | Baird | Initiate | Outperform |
| 2025-05-20 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-05-09 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
| 2025-05-08 | Needham | Maintains | Buy -> Buy |
| 2025-03-18 | Needham | Maintains | Buy -> Buy |
| 2025-02-07 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-02-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-02-07 | Needham | Maintains | Buy -> Buy |
| 2025-02-07 | Raymond James | Reiterate | Strong Buy -> Strong Buy |
| 2024-12-06 | JP Morgan | Initiate | Overweight |
| 2024-12-04 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-12-03 | Needham | Reiterate | Buy -> Buy |
| 2024-11-15 | Needham | Reiterate | Buy -> Buy |
| 2024-11-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-11-08 | Raymond James | Upgrade | Outperform -> Strong Buy |
| 2024-09-23 | Barrington Research | Maintains | Outperform -> Outperform |
HAEMONETICS CORP/MASS / HAE FAQ
What is the price target for HAE stock?
15 analysts have analysed HAE and the average price target is 88.03 USD. This implies a price increase of 8.21% is expected in the next year compared to the current price of 81.35.
Can you provide the consensus rating for HAEMONETICS CORP/MASS stock?
The consensus rating for HAEMONETICS CORP/MASS (HAE) is 81.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.